You are here: Home » Current Affairs » Coronavirus » News
I firmly believe our Quad would act as a force for global good: PM Modi
PM Narendra Modi reaches New York to address 76th UNGA session
Business Standard

Booster dose: Bharat Biotech's nasal vaccine may be used with Covaxin

The idea is to see which combination induces better and long-lasting immune response

Topics
Bharat Biotech | Coronavirus Vaccine | nasal vaccine

Sohini Das  |  Mumbai 



Bharat Biotech has also finished administering the vaccines for its paediatric trial of Covaxin. Now, it is analysing the data before it can submit it to the regulator for review.
Bharat Biotech has also finished administering the vaccines for its paediatric trial of Covaxin. Now, it is analysing the data before it can submit it to the regulator for review.

is working on a three-legged clinical trial for its intranasal vaccine BBV154, which is in phase two. The Hyderabad-based firm is testing the efficacy of a combination in three modes – two intranasal shots, first a Covaxin shot followed by the nasal vaccine, and Covaxin following a nasal shot.
 
The idea is to see which combination induces better and long-lasting immune response. Therefore, the intranasal vaccine could be used as a combination with the intramuscular Covaxin shot.
 
“While the can be administered as two shots, the company is testing whether combining it with Covaxin gives better results. Thus, this can be used as a mix-and-match with Covaxin to produce a more holistic immune response,” the source said.
 
The company did not answer some queries sent by Business Standard till the time of going to press.
 
The two vaccines have different mechanisms of action and trigger slightly different immune responses.
 
Shahid Jameel, senior virologist and director at Ashoka University, said a different kind of antibodies protects the nasal mucosa – these are called IgA antibodies. “This is not sufficiently generated when a vaccine is administered through the intramuscular route,” Jameel said.
 
Commenting on the nasal vaccine, Jacob John, former head of Centre for Advanced Research in Virology at the Indian Council of Medical Research (ICMR), said to have a is a ‘fantastic idea’ for two reasons — one, it can potentially create sterile immunity, and two, it is easy to administer and thus scalable.
 
Experts feel that when one gets sterile immunity in the nasal tract, one does not shed the virus, and this prevents transmission.
 
According to sources in the know, recruitments for the phase 2 trials are over. Around 650 volunteers are likely to be part of the trials. The first phase had 175 participants.
 
Meanwhile, has also finished administering the vaccines for its paediatric trial of Covaxin. Now, it is analysing the data before it can submit it to the regulator for review.
 

BOOSTER DOSE

Three-legged phase 2 trials will be done:

  • Two shots of intranasal vaccine BBV154 in 28-day interval
  • Covaxin as first dose followed by BBV154 
  • BBV154 as first dose followed by Covaxin

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Sat, September 25 2021. 06:06 IST

RECOMMENDED FOR YOU